Merck & Co. Inc. (MRK)

86.95
1.30 1.50
NYSE : Health Technology
Prev Close 85.65
Open 86.29
Day Low/High 86.13 / 86.76
52 Wk Low/High 66.10 / 87.07
Volume 1.02M
Avg Volume 9.92M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 217.79B
EPS 2.30
P/E Ratio 40.66
Div & Yield 2.20 (2.50%)
This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

Jim Cramer says there's still too much greed and complacency, and not enough fear and panic.

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

Jim Cramer is ready to call the Fed out. And he has your game plan ready for next week.

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared To Standard Of Care, As Monotherapy And In Combination With Chemotherapy, As First-Line Treatment For Patients With Recurrent Or Metastatic Head And Neck Cancer

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared To Standard Of Care, As Monotherapy And In Combination With Chemotherapy, As First-Line Treatment For Patients With Recurrent Or Metastatic Head And Neck Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of interim data from the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as both monotherapy and in...

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Melanoma

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA,...

(Graphic: Business Wire)

(Graphic: Business Wire)

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed...

First Presentation Of Early Data For Merck's Investigational STING Agonist (MK-1454) In Patients With Advanced Solid Tumors Or Lymphomas At ESMO 2018 Congress

First Presentation Of Early Data For Merck's Investigational STING Agonist (MK-1454) In Patients With Advanced Solid Tumors Or Lymphomas At ESMO 2018 Congress

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as...

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients...

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Inlyta ® (axitinib), Pfizer's...

Merck Announces Appointment Of Jim Scholefield As Chief Information And Digital Officer

Merck Announces Appointment Of Jim Scholefield As Chief Information And Digital Officer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct.

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation For Pancreatic Cancer

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation For Pancreatic Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from Merck's broad oncology portfolio and robust early pipeline will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in...

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO™, a once-daily fixed-dose combination tablet of doravirine (100...

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™, a once-daily fixed-dose combination tablet of...

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today a new effort to support cities across the country to help women have a healthy pregnancy and safe childbirth.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.

The New #13 Most Shorted Dow Component: Merck

The New #13 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 09/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that its Board of Directors has rescinded its policy subjecting the company's Chief Executive Officer to mandatory retirement at age 65.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing...

Merck and PPL Corp. Still Look Good Here

Both names have enjoyed recent price run-ups and continue to pay decent dividends.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with pemetrexed (ALIMTA ®) and platinum chemotherapy for the...

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that investigational data from the company's leading lung cancer research program with KEYTRUDA, Merck's anti-PD-1 therapy, will be presented at the IASLC 19th World...

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

TheStreet Quant Rating: A+ (Buy)